An observational study in FSH, FSH Muscular Dystrophy and FSHD - Facioscapulohumeral Muscular Dystrophy, sponsored by FSHD Society. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by FSHD Society · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 27th registered.
79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.
Browse Muscular Dystrophy, Facioscapulohumeral studies →8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:
Scholar Rock, Inc. · Sites in United States
Ages 18–60
Restem, LLC. · Sites in United States
Ages 15+
Jeffrey Statland · Sites in United States
Ages 18–75
Avidity Biosciences, Inc. · Sites in United States, Canada, Denmark and 7 more countries
Ages 16–70
University of Kansas Medical Center · Sites in United States, Australia
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 2
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 87 across 30 observational studies indexed under Muscular Dystrophy, Facioscapulohumeral.
Median enrollment 51 across the 21 interventional studies, 94 across the 11 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 32 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with FSHD Society as lead sponsor.
FSHD Society has 1 study filed under Muscular Dystrophy, Facioscapulohumeral — fewer than ten, so there is no comparison to draw.
3 of the studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847282University of Kansas Medical CenterMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | 2027-05 |
| NCT05019625Massachusetts General HospitalBiomarker Development for Muscular Dystrophies | 2027-06 |
| NCT06907875Epicrispr Biotechnologies, Inc.A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BetterLife FSHD is a registry platform built to support people living with FSHD. It connects patients with personalized resources, tools, and research opportunities that match their health experiences and needs. At the same time, BetterLife collects secure health and experience data from patients to support research. This data is shared with researchers to help better understand FSHD and work toward improved care, treatments, and outcomes for the community.
Learn more and enroll at: www.BetterLifeFSHD.org
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that causes relentless weakening of skeletal muscles. BetterLife FSHD is a patient-driven health platform and research registry that aims to help FSHD patients live their best lives while also powering research.
In BetterLife, participants are prompted to respond to a series of short surveys spread out over a quarterly and yearly basis. Survey topics include demographics, health history, FSHD diagnosis and progression, FSHD management strategies, and quality of life domains like pain, fatigue, and mental health.
As participants provide survey data, they receive a personalized feed of resources relevant to them from the FSHD Society's library of articles, blogs, videos, and webinars. Survey data is also used to inform participants which clinical trials and other research studies they may be eligible for.
The information that BetterLife FSHD collects is stored and managed in a modern and secure real-world data infrastructure. De-identified data is made available upon request to researchers, clinicians, biopharmaceutical companies, regulator/payor bodies, and other organizations involved in FSHD research and therapeutic development with approval from a steering committee. BetterLife can also be used to conduct and support research initiatives external to the FSHD Society.
People with FSHD living in the United States or its territories age one year or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observational study
Longitudinal Health Data
Survey questions to capture information on demographics, health history, FSHD diagnosis (clinical diagnosis, genetic testing, family history, etc.), and FSHD symptom management (e.g., use of assistive devices, ventilation, surgery).
Time frame: Assessed annually from enrollment until study completion (10 years)
Self Reported FSHD Progression
Survey questions that cover muscle weakness, symptom onset, and key progression milestones, and which can be used to estimate FSHD Clinical Score (FCS) . A higher score indicates more disease severity.
Time frame: Assessed every 6 months, until study completion (10 years)
Anxiety Patient Reported Outcome Measure
Assesses frequency and impact of anxiety symptoms using a 5-point rating system. Higher scores indicate more anxiety.
Time frame: Quarterly, until study completion (10 years)
Depression Patient Reported Outcome Measure
Assesses frequency and impact of depression symptoms using a 5-point rating system. Higher scores indicate more depression.
Time frame: Quarterly, until study completion (10 years)
Pain Patient Reported Outcome Measure
Assesses the quality of pain and interference with daily life using a 5-point rating system. Higher scores indicate higher levels of pain and interference.
Time frame: Quarterly, until study completion (10 years)
Sleep Patient Reported Outcome Measure
Assesses the quality of sleep using a 5-point rating system. Higher scores indicate poor sleep quality.
Time frame: Quarterly, until study completion (10 years)
Fatigue Patient Reported Outcome Measure
Assesses the presence and severity of fatigue using a 5-point rating system. Higher scores indicate more fatigue.
Time frame: Quarterly, until study completion (10 years)
Upper Body Patient Reported Outcome Measure
Assesses the ability to perform activities of daily living with the upper body using a 5-point rating system. Higher scores indicate less difficulty completing tasks using the upper body.
Time frame: Quarterly, until study completion (10 years)
Mobility Patient Reported Outcome Measure
Assesses the ability to perform activities with the lower body (i.e., standing up, sitting) using a 5-point rating system. Higher scores indicate less difficulty using the lower body.
Time frame: Quarterly, until study completion (10 years)
Physical Activity Patient Reported Outcome Measure
Assesses the amount of time spent engaged in physical activity in minutes. Higher scores indicate greater levels of physical activity.
Time frame: Quarterly, until study completion (10 years)
Falls Patient Reported Outcome Measure
Assesses fear of falling during daily activities using a 4-point scale. Higher scores indicate a greater fear of falling.
Time frame: Quarterly, until study completion (10 years)
Research Preferences
Survey questions where participants rank their willingness to participate in various research procedures, concerns about participating in research trials, and preferences for remote/in-person/hybrid study visits.
Time frame: Yearly until study completion (10 years)
Diagnostic Journey
Survey questions to describe participant experience and barriers getting diagnosed with FSHD.
Time frame: One time at Baseline
Healthcare Experiences
Survey questions to describe healthcare utilization and experiences navigating healthcare settings.
Time frame: Yearly, until study completion (10 years)
Women's Health
Survey questions about history of menstruation and pregnancy.
Time frame: Yearly, until study completion (10 years)
Social Determinants of Health
Survey questions about current employment status/job security, neighborhood, religious practices, discrimination, and food security.
Time frame: Yearly, until study completion (10 years)
Plan to share: Yes — All individual participant data (IPD) collected by BetterLife is made available to the research community in the form of de-identified or limited datasets upon request and approval by the Steering Committee.
Supporting information: Study protocol, Informed consent form
Time frame: IPD and supporting information were available beginning August 2024 and with no planned end date.
Access criteria: Researchers can request access IPD and supporting information. Researchers may include pharmaceutical or biotechnology companies, academic institutions, hospitals, or other organizations involved in research and therapeutic development. Government agencies or payor systems who make decisions about treatment approvals and access, for example, the Food and Drug Administration (FDA) or the Institute for Clinical and Economic Review (ICER) can also request access. To request access, researchers should visit www.BetterLifeFSHD.org or email BetterLife@FSHDSociety.org. Researchers must provide key details about their research project, including PI and study contacts, brief background information, clear study objectives, procedures, and outcomes, summary of importance for the field, and documentation of IRB approval, when required. All requests are reviewed by the Steering Committee. Projects that are approved must agree to a data use agreement.
Started Aug 2024 (actual). Primary completion is estimated for Jan 2060, 425 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Facioscapulohumeral →